Cas No. |
Product name |
198062-54-3 |
GW-311616 |
more... |
GW311616 is a potent, intracellular, orally bioavailable, long duration inhibitor of human neutrophil elastase(HNE) with IC50 of 22 nM. GW-311616 is the free base form of GW3... |
452342-67-5 |
GW788388 |
more... |
GW788388 is a new TGF-beta type I receptor inhibitor with a much improved pharmacokinetic profile compared with SB431542. We studied its effect in vitro and found that it inh... |
660868-91-7 |
GW843682X |
more... |
GW843682X is a selective inhibitor of polo-like kinase 1 (PLK1) and polo-like kinase 3 (PLK3) (IC50 values are 2.2 and 9.1 nM respectively). GW843682X inhibited the prolifera... |
1402821-41-3 |
GV-58 |
more... |
GV-58 is a potent, selective N- and P/Q-type Ca2+ channels agonist with EC50 of 7.21/8.81 uM for N-type/P-Q-type Ca2+ channel; 20-fold less potent CDK inhibitor activity. |
1616391-87-7 |
GSK591 |
more... |
GSK591, also known as EPZ015866, is a chemical probe for PRMT5. In an in vitro biochemical assay, GSK591 potently inhibits the PRMT5/MEP50 complex from methylating (histone) ... |
1372540-91-4 |
GSK2636771 |
more... |
1. The best quality,
competitive price.
2. The best service before or
after shipment.
3. Rich experience in export
op... |
1224887-10-8 |
GSK-2256098 |
more... |
GSK2256098, also known as GTPL7939, is a focal adhesion kinase-1 (FAK) inhibitor with potential antiangiogenic and antineoplastic activities. FAK inhibitor GSK2256098 i... |
844903-58-8 |
GSK163090 |
more... |
GSK163090 is Potent, selective, and orally active 5-HT1A/B/D receptor antagonist. GSK163090 was found to combine potent in vivo activity with a strong preclinical developabil... |
1253186-49-0 |
GSK-5498A |
more... |
GSK-5498A is a selective small molecule blocker of CRAC channel(IC50=1 uM); inhibit mediator release from mast cells, and pro-inflammatory cytokine release from T-cells in a ... |
929095-18-1 |
GSK-461364 |
more... |
GSK-461364 is a Polo-like kinase 1 inhibitor, is also a small molecule Polo-like kinase 1 (PLK1) inhibitor with potential antineoplastic activity. Polo-like kinase 1 inhibito... |